Morgans have just released a new report with an Add rating and an increased PT of 82c...
The moment of truth approaches
Although royalty income received from ACL’s lead product
fondaparinux was lower than expected, the main game is the Phase III
read out from the colorectal cancer program, expected in 2QCY14. A
positive result will not only validate the lead program but will
substantially underpin the HyAct technology, which has multiple
applications across other tumour types. In our modelling we have
assumed the lead program is licensed to a larger pharma company.
The investment case remains compelling with this near term catalyst.
- Forums
- ASX - By Stock
- TSN
- Ann: Fondaparinux Quarterly Profit Share
Ann: Fondaparinux Quarterly Profit Share , page-31
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable